SAG and cancer: Interestingly, the ß-arrestin biased ß-blocker carvedilol, a ligand that activates ß2AR-ß-arrestin2 signaling while inactivating canonical ß2AR-Gs signaling, has been found to be beneficial in cancer prevention by virtue of blocking a key step in carcinogenesis, i.e., ERK translocation into the nucleus (Wisler et al., 2007; Cleveland et al., 2018).